rs1044317 — ABCG1 ABCG1 3'UTR variant

3'UTR variant in ABCG1 that may reduce transporter expression, impairing cholesterol efflux to HDL and increasing susceptibility to coronary artery disease.

See your personal result for ABCG1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ABCG1 — The HDL Maturation Transporter

ABCG1 (ATP-binding cassette transporter G111 ATP-binding cassette transporter G1
a membrane protein that pumps cholesterol out of cells into HDL particles in the bloodstream) is one of two master regulators of reverse cholesterol transport — the biological system that removes excess cholesterol from artery walls and returns it to the liver for disposal. While its partner ABCA1 initiates cholesterol loading onto nascent HDL particles, ABCG1 takes over, pumping additional cholesterol and phospholipids onto maturing HDL. Together they determine how efficiently your body can clear cholesterol from macrophage foam cells in arterial plaques.

The rs1044317 variant sits in the 3' untranslated region (3'UTR)22 3' untranslated region (3'UTR)
the trailing sequence of the mRNA transcript after the protein-coding stop codon; it contains binding sites for regulatory microRNAs and elements that control mRNA stability and translation efficiency of ABCG1. Unlike missense variants that alter the protein's shape, this is a regulatory variant — it may affect how much ABCG1 protein your cells produce.

The Mechanism

The ABCG1 3'UTR harbors multiple microRNA binding sites33 microRNA binding sites
microRNAs are short RNA molecules that bind to the 3'UTR and suppress gene expression by blocking translation or triggering mRNA degradation. Research has demonstrated that miR-128-2, for example, binds directly to the ABCG1 3'UTR with complete seed-sequence complementarity, reducing both ABCG1 mRNA and protein levels dose-dependently. Variants in the 3'UTR can create or disrupt such binding sites, altering how responsive ABCG1 expression is to these regulatory signals.

The A allele of rs1044317 (the GRCh38 reference, but the minor allele at ~43% globally) appears to tag a lower-expression ABCG1 haplotype. Reduced ABCG1 activity impairs the second step of reverse cholesterol transport — cholesterol efflux to mature HDL — leaving macrophages more prone to cholesterol accumulation and foam cell formation, an early driver of atherosclerotic plaques.

The Evidence

A case-control study of 541 coronary artery disease (CAD) patients and 649 healthy controls from a Chinese Han population44 case-control study of 541 coronary artery disease (CAD) patients and 649 healthy controls from a Chinese Han population
Ma et al., Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010 found that the A allele of rs1044317 was significantly more frequent in CAD patients than controls (OR 1.187, 95% CI 1.009–1.397, p=0.039). While this is a single-population study, the finding is biologically consistent with ABCG1's role in preventing foam cell formation.

A larger case-control study of 1,021 CAD patients and 1,013 controls from the same population55 case-control study of 1,021 CAD patients and 1,013 controls from the same population
Xu et al., Atherosclerosis 2011 genotyped rs1044317 alongside other ABCG1 variants and confirmed that the ABCG1 locus on chromosome 21 is associated with CAD susceptibility in Han Chinese. The primary signal in that study came from a functional promoter variant (rs57137919, OR 0.73 protective), which may tag the same risk haplotype as rs1044317.

The mechanistic basis for ABCG1's cardiovascular role is well-established. A comprehensive review66 comprehensive review
Frambach et al. 2020 Pharmacological Reviews concluded that ABCA1 and ABCG1 expression and function are rate-limiting steps for cholesterol efflux and that enhancing their activity represents a therapeutic strategy beyond LDL reduction. When ABCG1 is compromised, macrophages in artery walls accumulate cholesterol and form foam cells — the hallmark of early atherosclerotic plaques.

Practical Actions

Carriers of one or two A alleles can support cholesterol efflux through several targeted strategies. Omega-3 fatty acids (EPA/DHA) upregulate ABCG1 expression in macrophages through PPAR-gamma and LXR pathways. Niacin (vitamin B3) is one of the few pharmacological agents that raises ABCG1 expression while also increasing HDL-C. Regular fasting or time-restricted eating activates autophagy and ABCG1 upregulation in macrophages, promoting cholesterol efflux. Monitoring HDL function (cholesterol efflux capacity test) rather than just HDL-C quantity can provide more actionable information for A allele carriers.

Interactions

ABCG1 works in concert with ABCA1 (multiple common variants including rs2853579 and rs4783244) in a two-step relay. Reduced function of both transporters simultaneously produces a greater impairment of reverse cholesterol transport than either alone. The LIPC variant rs12593008 affects hepatic lipase, which remodels the HDL particles that ABCG1 loads — compound effects on HDL pathway function are possible across these loci. CETP variants (rs708272) affect cholesteryl ester transfer from HDL to LDL/VLDL, adding a third node of variation in the same pathway.

Nutrient Interactions

omega-3 fatty acids increased_need

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Efflux Normal

Normal ABCG1-mediated cholesterol efflux capacity

You carry two copies of the G allele at rs1044317, the most common ABCG1 3'UTR genotype globally (~33% of the population is GG). This genotype is associated with normal ABCG1 expression and population-typical capacity for cholesterol efflux to HDL particles. Your reverse cholesterol transport machinery — the system that removes cholesterol from artery walls — is expected to function at baseline efficiency from this locus.

AG One Risk Allele Intermediate

One copy of the ABCG1 low-expression allele — moderately reduced efflux capacity

The ABCG1 3'UTR A allele may disrupt microRNA binding site regulation, reducing the efficiency of ABCG1 mRNA translation. With one functional G-allele copy alongside the A allele, ABCG1 expression is likely intermediate. Macrophage cholesterol efflux to mature HDL particles may be modestly reduced, which over decades of exposure to dietary cholesterol and saturated fat could contribute to subclinical atherosclerosis. The clinical significance of heterozygous status at this locus is moderate — it warrants attention, particularly if other cardiovascular risk factors are present.

AA Two Risk Alleles High Risk

Two copies of the ABCG1 low-expression allele — most impaired efflux capacity

The A/A genotype carries two copies of the 3'UTR allele associated with reduced ABCG1 expression. In the reverse cholesterol transport pathway, ABCG1 is responsible for the second-wave loading of cholesterol onto maturing HDL particles after ABCA1 initiates the process. Homozygous reduced expression means both copies of the ABCG1 gene may be less efficiently translated, potentially resulting in substantially less ABCG1 protein at macrophage membranes. Over time, impaired cholesterol export from macrophages in arterial intima promotes foam cell formation and early atherogenesis.

The strongest evidence comes from a Chinese Han cohort study showing the A allele significantly overrepresented in CAD patients, though the studies were conducted in East Asian populations and replication in European cohorts is more limited. Nonetheless, the biological mechanism — ABCG1 3'UTR regulation of expression — is well-established and not population-specific. Homozygous carriers benefit most from interventions that upregulate ABCG1 expression through complementary transcriptional pathways.